A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 17, Issue 3, 2015, Pages 194-202

  Ampudia Blasco, F Javier ^a   Benhamou, Pierre Yves ^b   Charpentier, Guillaume ^c   Consoli, Agostino ^d   Diamant, Michaela ^e   Gallwitz, Baptist ^f   Khunti, Kamlesh ^g   Mathieu, Chantal ^h   Ridderstråle, Martin ⁱ   Seufert, Jochen ^j   Tack, Cees ^k   Vilsbøll, Tina ^l   Phan, Tra Mi ^m   Stoevelaar, Herman ⁿ  

^a UNIVERSITY OF VALENCIA   (Spain)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^d UNIVERSITY OF CHIETI   (Italy)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ STENO DIABETES CENTER   (Denmark)

^j UNIVERSITY OF FREIBURG   (Germany)

^k RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m Novo Nordisk FemCare AG   (Switzerland)

ⁿ Centre for Decision Analysis and Support   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN DERIVATIVE; METFORMIN; PIOGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPUTER SYSTEM; DECISION SUPPORT SYSTEM; DIABETIC PATIENT; DRUG TOLERABILITY; GLYCEMIC CONTROL; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; LIFE EXPECTANCY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REIMBURSEMENT; UNCERTAINTY; BLOOD; CLINICAL PROTOCOL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG SUBSTITUTION; EUROPE; EXPERT WITNESS; HUMAN; PERSONALIZED MEDICINE; PROCEDURES; STANDARDS; SUPPLY AND DISTRIBUTION;

BODY MASS INDEX; CLINICAL PROTOCOLS; COMORBIDITY; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EUROPE; EXPERT TESTIMONY; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIFE EXPECTANCY; METFORMIN; PRECISION MEDICINE; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84923853384     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0260     Document Type: Article

References (29)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
2. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
3. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
4. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
5. Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 2014; 5: 141-147
6. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80, 000 people. Diabetes Care 2013; 36: 3411-3417
7. Kostev K, Rathmann W. Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). Prim Care Diabetes 2013; 7: 229-233
8. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8(6): 1-72
9. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011; 70: 818-822
10. Moro E, Allert N, Eleopra R, et al A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. J Neurol 2009; 256: 83-88
11. Reinisch W, Chowers Y, Danese S, et al. The management of iron deficiency in inflammatory bowel disease-An online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38: 1109-1118
12. Brook RH, Chassin MR, Fink A, et al A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53-63
13. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method. Santa Monica, CA. RAND, 2001
14. Lawson EH, Gibbons MM, Ko CY, et al. The appropriateness method has acceptable reliability and validity for assessing overuse and underuse of surgical procedures. J Clin Epidemiol 2012; 65: 1133-1143
15. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 2014; 80: 47-56
16. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013; 173: 1300-1306
17. McDonnell J, Stoevelaar HJ, Bosch JL, et al. The appropriateness of treatment of benign prostatic hyperplasia: a comparison of Dutch and multinational criteria. Health Policy 2001; 57: 45-56
18. Quintana JM, Arostegui I, Azkarate J, et al. Evaluation of explicit criteria for total hip joint replacement. J Clin Epidemiol 2000; 53: 1200-1208
19. Vader JP, Burnand B, Froehlich F, et al. Appropriateness of upper gastrointestinal endoscopy: comparison of American and Swiss criteria. Int J Qual Health Care 1997; 9: 87-92
20. Wilkinson MJ, Nathan AG, Huang ES. Personalized decision support in type 2 diabetes mellitus: current evidence and future directions. Curr Diab Rep 2013; 13: 205-212
21. Cleveringa FG, Gorter KJ, van den-Donk M, et al.combined task delegation, computerized decision support, and feedback improve cardiovascular risk for type 2 diabetic patients: a cluster randomized trial in primary care. Diabetes Care 2008; 8: 2273-2275
22. Rodbard D, Vigersky RA. Design of a decision support system to help clinicians manage glycemia in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 2011; 5: 402-411
23. Vigersky RA, Galen RS, Horne D, et al.computer assisted decision support (CADS) for primary care of diabetes[abstract]. Telemed J E Health 2007; 13(2): 168
24. Ceriello A, Gallo M, Candido R, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 2014; 7: 129-136
25. Cleveringa FG, Gorter KJ, van den Donk M, et al.computerized decision support systems in primary care for type 2 diabetes patients only improve patients' outcomes when combined with feedback on performance and case management: a systematic review. Diabetes Technol Ther 2013; 15: 180-192
26. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005; 293: 1223-1238
27. Purcell GP. What makes a good clinical decision support system. BMJ 2005; 330: 741-742
28. Kawamoto K, Houlihan CA, Balas EA, et al. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005; 15: 765
29. Sim I, Gorman P, Greenes RA, et al. Clinical decision support systems for the practice of evidence-based medicine. J Am Med Inform Assoc 2001; 8: 527-534